Eur Rev Med Pharmacol Sci 2020; 24 (17): 9208-9215

DOI: 10.26355/eurrev_202009_22873

Advances in SARS-CoV-2: a systematic review

Y.-X. Bai, Y.-H. Xu, X. Wang, C. Sun, Y. Guo, S. Qiu, K.-W. Ma

Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China. makw@jlu.edu.cn


OBJECTIVE: In December 2019, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection broke out in Wuhan, China. However, we still lack a comprehensive understanding of this emerging virus. In this manuscript, we collected relevant articles and reviewed the characteristics about SARS-CoV-2.

MATERIALS AND METHODS: We performed an online search on PubMed and Web of Science with the keywords COVID-19, 2019-nCoV and SARS-CoV-2, and summarized the epidemiology, virology, clinical features and treatments of SARS-CoV-2 infection.

RESULTS: We retrieved 157 published papers about SARS-CoV-2 from January, 2020 to April, 2020. We found that SARS-CoV-2 was a kind of virus with low mortality rate and high infectivity. This virus can enter human cells through angiotensin-converting enzyme 2 (ACE2) in alveoli and activate immune response in human body. SARS-CoV-2 infection can be classified as asymptomatic, mild, common, severe, and critical. We summarized antiviral drugs against SARS-CoV-2, such as remdesivir, hydroxychloroquine and favipiravir. Because the vaccine of SARS-CoV-2 is developing, more clinical studies are needed to verify the safety and efficacy of these treatments.

CONCLUSIONS: SARS-CoV-2 is a novel coronavirus that has caused a global pandemic. We should pay more attention to prevent SARS-CoV-2 and try to control it sooner.

Free PDF Download

To cite this article

Y.-X. Bai, Y.-H. Xu, X. Wang, C. Sun, Y. Guo, S. Qiu, K.-W. Ma
Advances in SARS-CoV-2: a systematic review

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 17
Pages: 9208-9215
DOI: 10.26355/eurrev_202009_22873